Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Online car parking games, new car parking games, flash games.
Popular Articles

Cedars-Sinai Women's Heart Center Launches Advanced Preventive Women's Clinic For Women With Menopause Symptoms Who Are At Risk For Heart Disease
Women who are at risk for heart disease and who are also experiencing menopause symptoms now have an added re - a highly specialized clinic in the Division of Cardiology at the Cedars-Sinai Heart Institute. The Advanced Preventive Women"s Clinic at the Women"s Heart Center recently opened and is offering comprehensive cardiac risk assessments designed specifically for women who are in menopause. The clinic also offers menopausal patients state-of-the-art screenings, as well as personalized medicine therapies and counseling, including high-risk hormone counseling.
generic viagra online
Alzheimer's Comment On Research That Genes In Early Onset Are Associated With Memory, Published In Nature, 28 July 2009
Memory is a fundamental function of nerve cells in the brain, and loss of memory is a key symptom in many people with Alzheimer"s disease.
News of the day
BIO Comments On White House Letter On Biosimilars
Biotechnology Industry Organization (BIO) President and CEO Jim Greenwood issued the following statement regarding the letter sent yesterday from the Obama Administration to House Energy and Commerce Committee Chairman Henry Waxman regarding biosimilars:
Public Health

BioCis Pharma Starts A Phase I Clinical Trial With A New Cancer Drug

BioCis Pharma Ltd., a privately-held drug development company with its headquarters in Turku, Finland, has started Phase I clinical testing of ProtoCure(TM) intravesical instillation solution, a novel anti-cancer drug for urinary bladder cancer. ProtoCure is based on a new mechanism of action discovered and developed by BioCis Pharma which effectively prevents cancer growth and proliferation locally. The open-label, dose-escalating study is designed to evaluate the safety, tolerability and pharmacokinetics of the locally administered (into the bladder) product in a total of 22 patients with primary or recurrent non-muscle invasive bladder cancer and it is expected to be well tolerated. "We are pleased to advance to clinical testing with the ProtoCure instillation solution," says Lasse Leino, CEO of BioCis Pharma. "It is our first oncology product to reach this important milestone and follows the initiation of two phase 2a studies with our leading anti-inflammatory product in patients with inflammatory skin disorders that we recently announced. The ProtoCure cancer drug holds great promise for patients suffering from superficial bladder cancer. We are committed to take the product quickly to more extensive clinical efficacy testing after this preliminary safety study. We expect to get results from this study by the first quarter of 2010." Bladder cancer is the fourth most common cancer in men and tenth among women. In addition, the recurrence rate is high, being almost 70 % in patients with the non-invasive form of the cancer, where the malignancy is typically found in the surface layers of the bladder. Non-invasive bladder cancer is treated by urologists using local surgery and intravesical drug therapy administered directly into the bladder. Existing drug therapies often have undesirable side effects and limited efficacy. BioCis Pharma Ltd is an innovative drug development company developing drug therapies based on a novel, patented therapeutic principles that target unmet medical needs in substantial therapeutic markets including inflammation, allergy, and cancer. The company"s main investors are Karolinska Development AB (publ.), Finnish Industry Investment Ltd., and Etra Invest Oy. BioCis Pharma Ltd


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009